2009 4th Medical Biotech Forum

Registration

Information

Program

Business

Sponsorship Opportunities

Exhibition

market report link

Biotechnology Market Research

Speakers

Sang Guowei,
Vice-Chairman, 11th Standing Committee of the NPC, China
Vice-Chairman, 11th Standing Committee of the NPC; Chairman, Chiese Peasants and Workers Democratic Party

Sang Guowei, male, Han nationality, is a native of Wuxing District, Zhejiang province. He was born in 1941, and graduated from the pharmacology department of the First Medical College of Shanghai in 1966. He is a doctoral tutor and academician of the Chinese Academy of Engineering. He was awarded the National Prize for Progress in Science and Technology several times. Professor Sang was also awarded the Medical Sciences Prize of the HLHL Foundation in 1997.
He joined the Chinese Peasants and Workers Democratic Party in 1996, and he was elected chairman in 2007. He is a standing committee member of the NPC and deputy director of the Education, Science, Culture and Public Health Committee of the NPC.
In 2008 he became Vice-Chairman of the Standing Committee of the 11th NPC.

Wu Zuze
Wu Zuze, male, Han nationality, is native of Zhenhai, Zhejiang Province. He graduated from Shandong University in 1957 and is an experimental blood specialist.

Wu's academic achievements include research on double phase character mechanisms. He illustrated that a double phase character mechanism existed between radiation damage and accumulated irradiation doses under continuous irradiation of acute and low dose rate "g" rays. His studies led to animals being verified in a disease course of sequent radioactive accidental cases.
He also applied chromosome and sex determination genes as genetics markers, unveiled the unevenness of hematogenous stem cell group and researched the performance and dynamics of liver hematogenous stem cell in human embryo development. His studies provided a theoretical basis for clinic transplant embryo liver hematogenous stem cell. In addition, he proved that there were three kinds of factors, hematogenous stimulating factor, liver cell growth factor and low modular tumor prohibitor existing in embryo liver. He was the first to achieve liver cell growth factor from a human liver with molecular weight of 13 thousand Doulton. Most recently, he developed an experimental treatment for multiple gene tumors, such as P53, B7-1 and GM-CSF.
He has served as a researcher at the Military Academy of Medical Sciences and was elected as an academician to the Chinese Academy of Sciences in 1993.

Qiang Boqin
Professor. Chairman of the Biochemistry Department, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences. Director of the Chinese National Human Genome North Center and Chairman of the Academic Board of the

Center. Member of the Experts Committee for National High-tech R&D Program (863 Program) in the Field of Biology and Modern Agriculture Technology. Academician at the Chinese Academy of Sciences.

Lu Shibi
Lu Shibi, male, Han nationality, is a native of Yichang, Hubei Province. He was born in 1930, and graduated from an 8 year course at the Clinic Department of Xiehe Medical College in 1956. Lu Shibi has been a resident, physician-in-

charge, assistant chief physician, associate professor, chief physician, and professor of the Department of Orthopedics at the Head Hospital of the PLA, and became its head in 1979. He is presently the head of the Osteology Institute of the PLA.
Lu's most important scientific achievements include, the creation of an artificial joint made with titanium and treatment of peripheral nerve injury by firearm with free nerve transplantation the manufacture of an artificial hip joint made with cobalt-chromium-molybdemum alloy of pearl surface.
He also conducted several experiments and clinical studies on artificial joints. Some of this studies included experiments with cartilage coloboma of the hip joint using auto-free periosteal transplantation. Among his other studies, Lu studied microscopic reconstructive surgery in the repair of the junctions of the four limbs and a study on the treatment of scorch neuralgia with pressure deduction on the peripheral perineurium.
Lu has won several awards for his innovative research.

Zhen Yongsu
Zhen Yongsu is a professor and chairman of the Department of Oncology, Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences and Peking Union Medical College. He is one of the pioneers in the research on

and development of antitumor drugs, especially antitumor antibiotics, in China. He has developed new models and assays for screening of antitumor drugs. As a principal investigator, he has studied and developed a series of antitumor antibiotics, including zhengguangmycin, guanghuimycin, pingyangmycin, boanmycin, and lidamycin. Among them, pingyangmycin has been widely used in clinical cancer chemotherapy in China over 26 years and listed as national essential drug. He demonstrated for the first time in China that a nucleoside transport inhibitor can be used to enhance the efficacy of antitumor drugs and pointed out that nucleoside transport can serve as a target for cancer chemotherapy. His published paper on this topic has been widely cited. Based on the study of nucleoside transport inhibitors, he has found several antitumor biochemical modulators of natural origin. In the field of biotechnology medicines, he has prepared several monoclonal antibody immunoconjugates and fusion proteins for cancer. In particular, he has made new progress in molecule downsizing of antibody-based conjugates and fusion proteins. He has published over 200 scientific articles. As chief editor, he has published three professional books, i.e., Antibody Engineering Drugs, TEA: Bioactivity and Therapeutic Potential (in English), and Antitumor Drug Research and Development. He won the second prize of the National Invention Award for the study of pingyangmycin and the Scientific Achievement Award at the National Science Congress for the study of zhengguangmycin. In addition, he won three prizes of the Science and Technology Advancement by the ministry, and the title of the National Scientist with Distinguished Contributions in 1986. He won Ho-Leung-Ho-Lee Prize for Science and Technology Advancement in 2001.

Liu Depei
Prof. Liu, born on May 4th, 1950 in Funan County of Anhui Province, China. He graduated with Ph. D degree of Biochemistry and Molecular Biology from Peking Union Medical College (PUMC) in 1986, and was elected as Member of

Chinese Academy of Engineering (CAE) in 1996. Now Dr. Liu is a professor of medical molecular biology, president of Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC) and Vice-President of the CAE.
At the National Laboratory of Medical Molecular Biology, Dr. Liu has been engaged in researches on molecular biology about the regulation of gene expression, transgenic animals and disease models, gene transfer and gene therapy. In the studies of the regulation of hemoglobin gene expression and gene therapy for ¦Â-thalassemia, he discovered firstly erythrotic specific enhancer (HS2) of ¦Â-globin gene and its critical NFE 2/AP I site, discovered that erythrotic specific enhancers in different lengths enhance ¦Â-globin gene expression level in retrovirus vector mediated gene transfer, and established transgenic mouse models of ¦Â E and ¦Â41/42 genes. Dr. Liu also found that TC1 transposon inversion in high frequency in mammalian cells, proved Locus Control Region and proximal regulation elements corporately direct developmental regulation of ¦Â-globin gene cluster, created BAC mediated a/b-gene cluster and human apolipoprotein AI/CIII/AIV/AV gene cluster transgenic animal models, discovered that Myleran could enhance fetal ¦Ã-globin gene expression level apparently in adult anemic Rhesus monkeys and ¦Â-thalassemia patients, and completed ¦Â-globin gene site specific mutation by chimeric oligonucleotides.
Thus far, Dr. Liu has more than 100 academic papers published in domestic and international journals, of which 52 papers are published in journals cited by Science Citation Index (SCI) and the cited number of his papers exceeds 200.
Due to his prominent work and achievements in scientific research and administrative management, Dr. Liu was awarded several times by the State Council, Ministry of Education, Ministry of Health of P. R. China and Beijing Municipal Government.

Zhao Kai
Professor Zhao Kai is a medical virologist, a senior scientist and former president of Beijing Institute of Biological Products. He began his career in 1954. He has devoted his life to the research on and the development of viral vaccine.

He developed cell culture vaccinia (smallpox vaccine) and BRD-II strain rubella vaccine in China.
In 1982, he led the research and pilot production project of plasma-derived Hepatitis B vaccine. By using the plasma with high titer HBsAg and main procedures of antigen purification, virus inactivation and adjuvantation, he established the technological process with high safety and high quality standard assurance. By vaccinating the infants born from the HBsAg and e antigen positive mothers with three shots, the rate of interruption of HBV perinatal transmission reached 80 percent. This HB vaccine was put into production in 1986.
In cooperation with Shanghai Institute of Biochemistry, Zhao was in charge of the pilot production of recombinant vaccinia virus derived HB vaccine. The HB vaccine was proved to be safe and efficacious through clinical trial, and won the New Drug Certification in 1991.
In order to upgrade the production line with the advanced technology, he led a project to import an industrial production technology of recombinant yeast derived HB vaccine from Merck Co. Inc. in 1993. By digesting and improving the imported production technology, the output has been increased substantially. The efficacy of the interruption of HBV perinatal transmission of recombinant yeast derived HB vaccine is superior to the other vaccines, up to 90 percent. The improved output and quality of vaccine meet the need of vaccination for neonates in China.
Thanks to the above-mentioned achievements, Zhao has won eight Awards for Scientific and Technological Progress by the state and the Ministry of Health, and three new drug certifications. He has published more than 80 papers and edited and published 13 books.

Shen Beifen
Chief of the Research Office of the Basic Medical Research Institute at the China Military Medical Science Academy,
China Shen Beifen, male, Han nationality, was born in 1943. His ancestral home is Kunshan, Jiangsu Province and

graduated from the Biological Department of Fudan University.
Awarded sixteen science and technology progress prizes by the military, Shen was elected for four years as a member of the expert committee of biological technology at the 863 Project.
The following year, in 1988, Shen spent the year as a researcher at the National Sanitation Research Institute of America. He later presided over the molecular immunology research institute of the Military Medical Science Institute.
An academician of the Chinese Academy of Engineering, Shen serves as the chief of the research office of the basic medical research institute at the China Military Medical Science Academy.

Hao Xishan
President of Tianjin Medical University, China
Hao Xishan, male, Han nationality, is a native of Hebei province. He was born in 1945, and graduated from Tianjin

Medical University. He is a professor of oncology at Tianjin Medical University. Hao studied oncological immunopathology in the U.S. and in Holland in 1980. During that period, he developed a new method to determine the content of interferon with radioimmunoassay as an objective index to measure the immunological function of the human t-cell. He also established a specific mouse t-cell line which could produce the related antigen to human intestines and stomach cancer.
Hao became president of Tianjin Medical University in 1994. He was appointed as an academician of the Chinese Academy of Engineering in 2003. He won the second prize of the State Progress of Science and Technology in Medical Science Award and the first prize of the Medical Science and Technology Award.

Cao Xuetao
Xuetao Cao, immunology expert. Chinese Academy of Engineering.
July 1964 19 Born in Jinan City, Shandong Province. 1990 graduated from Second Military Medical University, Ph.D.,

currently vice president of the Second Military Medical University, Second Military Medical University, Immunology Institute, Doctor.
On dendritic cells (DC) of tumor immunology and immune and gene therapy carried out systematically in depth and innovative basic research and clinical applied research. Found an important immune regulatory function of a new type of DC subsets, and found that the role of mature DC in the matrix under the further proliferation and differentiation; DC made a new mechanism of immune regulation and found that it has two types of new features. Autonomy from the DC found a total length of 124 new genes and studied the function of more than 20, found 12 kinds of new elements was officially named HUGO. Immunization with a tumor gene therapy and new ways to carry out its applied research. SCI Indexed 112 journal papers, in addition, cooperation with domestic and foreign scholars published in Nat Med, such as SCI included seven papers, the papers were cited 833 times SCI him. Preparation and co-editor of three monographs, AP 10.
By the National Natural Science Award for a second-class, national scientific and technological progress a third prize of Shanghai a first prize of scientific and technological progress, the military progress of science and technology a first prize, second prize two. The first person to complete the National Certificate II Class 2 drugs, 10 National Invention Patent.

Zeng Yixin
Zeng Yixin, academician of Chinese Academy of Sciences (CAS), male, was born in Lianyuan City, Hunan Province in October 1962. After graduation from Sun Yat-Sen University of Medical Sciences with a doctor degree in 1990, he studied

abroad in Japan and American until 1997 when he returned to China and began to work in the Cancer Center of Sun Yat-sen University. He once served as the director of the Cancer Center as well as several national or provincial key laboratories, such as the Laboratory for Diagnosis and Treatment of Nasopharyngeal Cancel, the Laboratory for Cancer Genomics & Anti-cancer Drug Research and the South China Laboratory of Tumor Biology. He is also the vice president for the Chinese Anticancer Association and the International Association for Research on Epstein-Barr virus and Associated Diseases, the editor-in-chief of the Chinese Journal of Cancer, and a member of the board of editors of Science in China, Cell Cycle and Cancer Biology and Therapy. In November 2005, he was selected as the academician of Chinese Academy of Sciences.
With his work mainly focusing on the episode mechanism of malignant tumor, he has made outstanding achievements in the research of genetic susceptibility of the nasopharyngeal cancer and the anti-cancer drug. His studies on the nasopharyngeal cancer has been regarded as a break-through in China's genome research for major and complex diseases in recent years and published in authoritative journals such as Nature Genetics and Caner Research, receiving recognition from the international medical circle. Up to now, Professor Zeng has published 133 papers, among which 57 are included in SCI-indexed journals and have been cited by SCI papers for 1032 times.
Since 1997 Doctor Zeng has won support from the Outstanding Young Scientist Foundation of China and nine national research projects such "863" and "973". In recognition of his brilliant accomplishments in both research and teaching, he has been awarded many honorary titles, such as 100-1000-10000 Talent Project, Outstanding University Teacher of Ministry of Education, Outstanding Young and Middle age Expert of Ministry of Health and State Council's Special Allowance Expert.

Sun Yan
Sun Yan, professor, chairman doctor, doctoral student adviser, cure of name of Chinese academy of medical sciences, academician of Chinese Academy of Engineering. Identity of Cengyi's visiting professor is engaged in considering in

center of American M.D.Anderson tumour. Currently hold the post ofChina academy of medical sciences, assist with new drug of state of hospital of medical university tumour (fight tumor drug) vice-chairman of foundation of research of cancer of chairman of institute of clinical tumour of director of clinical research center, Asia, China, China fights cancer to learn center of clinical oncology cooperation committee member of advisory committee of expert of cancer of committee member of directive committee chairman, World Health Organization.
Professor Sun Yan founded internal medicine of our country tumour to treat major. Fu Zhengpei of the " in motherland medicine the remedial law of this " and contemporary and clinical immunology are united in wedlock, began with collaboration of domestic and international expert help up in the middle of of action of medical hurried immunity clinical study with the experiment. 40 will be engaged in tumor internal medicine all the time for years clinical cure and experimental research work, develop therapeuticly for internal medicine of our country tumour, rise, develop and innovate made outstanding contribution.

Tang Zhaoyou
Zhao-You Tang (1930-), graduated from Shanghai Medical University in 1954. He is currently professor of surgery and chairman of Liver Cancer Institute of Fudan University (previous Liver Cancer Institute of Shanghai Medical University),

member of Chinese Academy of Engineering (1994-), vice president of Chinese Medical Association (CMA, 1989-), vice chairman of Oncology Society of CMA (1990-).
He had been president of Shanghai Medical University (1988-94), UICC council member (1990-98), chairman of Liver Cancer Society of Chinese Anti-Cancer Association (1985-99), liver cancer session chairman of 15th and 16th International Cancer Congress and Chairman of 1986, 1991, 1996 Shanghai International Symposium on Liver Cancer and Hepatitis.
Tang has devoted in the research of hepatocellular carcinoma (HCC) for 30 years, and resulted in improvement of prognosis of HCC. Tang's contribution was mainly early detection, early diagnosis and early treatment of HCC, which was summarized as "Study on small / subclinical HCC". To this end, Tang has made every effort to bridge the basic findings and clinical application. A concept of "subclincial HCC" has been advocated. This concept was included in "Progress in Liver Diseases" edited by Hans Popper in 1982, and being summarized in the book entitled "Subclinical HCC" edited by Tang (Springer 1985). Hans Popper mentioned in the preface of this book: "This concept represents major progress in the understanding, and particularly the management, of HCC". He won a gold medal from Cancer Research Institute, New York, USA in 1979, and 1st National Prize for Progress of Science and Technology, P.R.China in 1985.
In the 1980s, the experience of small HCC studies was extended to the study of "conversion of large unresectable to small resectable HCC, and followed by 2nd stage resection ". He won the 3rd National Prize for Progress of Science and Technology, P.R.China in 1991. Efforts made in the last two decades have resulted in marked increase of 5-year survival rate in the entire series of HCC.
In the 1990s, in order to improve prognosis further after resection, "studies on recurrence and metastasis" has become a major target of study in Tang's group. A metastatic human HCC model in nude mice and a cell line with high metastatic potential have been established, which were known as the first metastatic human HCC model.
He had edited 6 books and published more than 400 papers, 70 of them included in SCI and cited by 658 papers. In 1998, he won another 3rd National Prize for Progress of Science and Technology, P.R.China for the book of "Contemporary Oncology" that he edited.

Ruan Changgeng
From 1979 to 1981, Professor Ruan Changgeng worked on the first monoclonal antibody (MoAb) to human platelet glycoprotein (GP) I, AN51, and elucidated that GPIb on the platelet membrane is the vWF receptor in the process of

platelet adhesion by using MoAb AN51. Under his direction, an internationally recognized SZ-series MoAbs against platelet membrane GPs and its agonists (vWF, fibrinogen etc.) has been developed in Thrombosis and Haemostasis Research Unit, which was set up at Suzhou Medical College in 1981.
To date, a number of important research projects have been undertaken by Ruan, including two projects of the International Atomic Energy Agency (IAEA), two from the Sino-France Programme de Recherche Advancee (PRA), one supported by the national "863" initiatives, four key projects of China's Seventh, Eighth, Ninth and 10th Five-Year plans and about 30 projects of the National Foundation of Natural Sciences (NFNS) and the ministry or the province.
Ruan has published four scientific books (in Chinese) and more than 400 scientific papers, of which about 60 papers were published in international journals. He has also won three national scientific prizes and 22 prizes at ministerial or provincial level and obtained three patents in China.

Chen Zhinan
Academician of Chinese Academy of Engineering, Professor and director of Cell Engineering Research Centre & Department of Cell Biology, National Key Discipline of Cell Biology, the Fourth Military Medical University. Doctoral tutor

and national excellent teacher. Chief expert of Vaccine & Antibody Stress Project, HTRDP of China, principal investigator of State Key Laboratory of Cancer Biology, standing council of Chinese Association of Cancer, director of Chinese Society of Tumor Marker Oncology, standing syndic of Chinese Society of Cell Biology, director of committee of Cell Engineering & transgenic Organism, vice director of Committee of Biochemistry & Biopharmaceutical, CPA. Professor Chen has been engaged in research on the cancer cell biology, cell engineering, antibody & biopharmaceuticals etc for long-term and obtained many advanced and creative fruits, especially in the fields of monoclonal antibody HAb18 with its target molecular CD147 and the extracellular matrix. From 1994, Professor Chen began to apply antibody target drug, named Iodine (131I) Metuximab Injection (LICARTINTM), obtained Certificate of New Drug in April 2005, certificate of GMP in January 2007 and came into the market.

Yao Kaitai
Professor Yao Kaitai, male, Han nationality, born on April, 1931 in Kunshan, Jiangshu province, graduated at the First Medical College of Shanghai in 1954.

Since 1975, Professor Yao Kaitai has been engaged in research work on epidemiology and cell biology of malignant tumor, experimental pathology and molecular biology of nasopharyngeal carcinoma and molecular genetics of cancer , etc. He has successively taken the state key projects of six-five, seven-five and eight-five planning, obtained fourteen NSFC programs and some CMB projects, and assumed more than thirty scientific research projects of the National Ministry of Education, the Ministry of Health and Science department, education department and health office of Hunan province. For his research achievements, he successively won the achievement prize of national science and technology congress, the second-class prize of national progression in science and technology, the third-class prize of national invention and many prizes at the province and ministry levels. In 1990, he was awarded the first batch of the special government subsidy and conferred "middle-aged and young expert with outstanding contributions". He was also appraised excellent teacher and model worker of the province or the country for many times. In 1991, Professor Yao Kaitai was elected member of the Chinese Academy of Sciences. Currently he is the head, professor and doctor supervisor of Cancer Research Institute, Central South University, vice president of Hunan Science Association, standing member of Chinese Anti-cancer Association, director committee member of Tumor & Leukemia Council of the National Pathophysiology Association Society, director of Hunan Anti-cancer Association and member of the discipline appraisal group of the Academic Degree Committee of the State Council.

Yao Xinsheng
Yao Xinsheng, male, Han nationality, is a native of Shanghai. He was born in 1934 and graduated from Northeast Medicinal College (presently Shenyang Medicinal University) in 1955. He studied in Japan from 1981 to 1983 and

earned a doctorate degree.
Yao remained at his alma mater upon graduation and served as an assistant lecturer. In 1960, under the tutelage Zhu Yanru (a well-known chemist), Yao helped establish the Natural Medicine Chemistry Research Office at the university. He later held lecturer and office chief positions before leaving for studies in Japan.
Elected as an academician to the Chinese Academy of Engineering in 1995, Yao was appointed president of the university in 1996 ¨C a post he held for four years. In 2000, he resigned the presidency to pursue his medicine research interests. In doing so, Yao created the Shenzhen Chinese Medicine and Natural Medicine Research Center.
He is the host of the medicinal appraisal group of the degree appraisal group at the State Council and also serves as the deputy director of the China Medicine Society.

Wen Lishi
Wen Lishi, male, Han nationality, is a native of Wuhan, Hubei Province. He was born in 1936 and graduated from the Physics and Chemistry Department of Moscow Steel Institute in 1960.

An expert in thin membrane and Nami technology, Wen has explored plasma technology and its application in surface protection. His results in plasma technology and satellite recovery antenna heat-resistant coating received awards from Liaoning province; Wen's research on satellite and thermal antenna won him first and third prizes of National Scientific Progress. His paper, "Nami Compound Electromagnetic Function Material Application Technology," won him a second prize for scientific progress from the Aviation Industrial Corporation of China.
A researcher at the Metal Research Institute of the Chinese Academy of Sciences, Wen was elected as an academician at the Chinese Academy of Sciences in 1999.

Guo Yinglu
Guo Yinglu is the leader of the new generation in the field of urology and andrology in China. He has been chief editor for 27 books, published more than 300 papers and won awards for more than 20 scientific projects. In 1982,

he was in charge of the investigation and production of the first generation of extracorporeal shock wave lithotripter in China, which was used clinically to treat renal stone in 1984. He was the first urologist in the world to use the prone position for extracorporeal ureter lithotripsy and is the pioneer in the field of extracorporeal shock wave lithotripsy. In the 1980s, he took the lead in China in doing microvasive procedures, such as transurethral resection, ureteroscopy, percutaneous nephroscopy and laparoscopy, and edited the first professional book for renal transplantation Renal Transplantation. In 1991, he edited the first book Endourology in this field and became the founder of Chinese endourology. In 1995, he founded the Chinese Andrology Society and the Urologist Training College of Peking University and in 2005, he set up the Chinese Urological Doctor Association. He also founded the Andrology Center of the Peking University First Hospital and made it work well and the best center in this field in China. For many years, Guo has made great contributions to the quick development of Chinese urology by consistently opening up new fields and bringing forth new ideas.

Gu Jianren
Gu Jianren was born in Suzhou, Jiangsu, on Jan. 13, 1932. He graduated from the First Shanghai Medical College in 1954. As a molecular oncologist, he is director of National Laboratory For Oncogenes and Related Genes, Shanghai

Cancer Institute, professor of molecular oncology in Shanghai Medical University, the member of National Biotechnology Program Board, the executive scientist of National Key Program For Human Gene Therapy. In 1994, he has elected to be the member academician of Chinese Academy of Engineering. Since 1995, he has been member of Award Assembly of General Motros Cancer Research Foundation.
He is the pioneer of molecular oncology and gene therapy research in China. In early 1960s, he demonstrated that the malignant phenotype of mouse hepatoma cells can be reversed towards that of normal hepatocytes in glycolytic metabolic pathways accompanied with inhibition of cancer cell growth by RNA extracted from normal animal liver. Since 1980s, his laboratory has devoted to the exploration of activated oncogenes and inactivated cancer suppressor genes involved in the development of human hepatocellular carcinoma (HCC). A number of protooncogenes or growth factor and receptor genes, such as N-ras, c-myc, c-ets 2, IGF ¢ò and its receptor IGF ¢ñ R and IGF ¢ò R, CSF ¢ñ and CSF ¢ñ R as well as EGF R were activated in HCC. Among the above genes, IGF ¢ò, CSF-¢ñ and TGF¦Á and their receptor genes were demonstrated as multiple autocrine.paracrine systems involved in the hepatocarcinogenesis as well as progression of HCC. Therefore, in early 1980s he addressed the concept that each type of human cancer should have a spectrum of activated protooncogenes and inactivated cancer suppressor genes involved in the different stages of carcinogenesis and progression of malignant disease.
In the late 1980s, his laboratory initiated the genome study related to human HCC. He firstly proved that p53 mutation rate among the HCC samples derived from different geographical areas had remarkable difference, therefore, indicating that p53 mutation may be not a unique event in majority cases (>85%) of HCC development. On the contrary, the loss of heterozygosity (LOH) of chromosome 17p13.3 was demonstrated in more than 50% HCC cases without any geographical differences. Since 1992, his laboratory has focused on the positional cloning of the 17p13.3 region. Large scale sequencing of a hot spot within this area will be collaborated with GeneCore Inc. The isolation of cDNA clones and characterization of their structure and function in his laboratory is in progress. The other aspect of the genomic research has been performed using EST techniques by screening the differentially expressed cDNA clones derived from heart, liver, HCC cDNA libraries as well as subtractive cDNA libraries from liver minus HCC or HCC minus liver. So far, at least 4 full-length cDNA clones with potential valuem either as novel sequences or know genes with novel function have been identified.
His contribution in human gene therapy is to develop the first cancer clinical trial of brain tumor (HSV-TK) in China. He constructed a novel gene delivery system targeting to cancer cells that was patented in 1996.

Wei Yuquan
Professor. Vice President of Sichuan University, Member of the Chinese Society of Clinical Oncology, Youth Member of the China Society of Medical Genetics. Academician at the Chinese Academy of Sciences.

Patrick A. Baeuerle
Mr. Baeuerle has served as Micromet's Chief Scientific Officer since October 1998. From February 1996 to September 1998, Mr. Baeuerle headed the drug discovery activities of Tularik Inc. in South San Francisco, CA, as Director, Drug

Discovery. From October 1994 to February 1996, Mr. Baeuerle served as a full Professor and Chairman of Biochemistry at the Medical Faculty of Freiburg University, Germany. In 1989, he was awarded a group leader position at the Gene Center in Martinsried, Germany, where he did seminal research on transcription factor NF-kappaB. According to a survey by the Institute for Scientific Information (ISI, Philadelphia, PA, USA), Mr. Baeuerle was Germany's most frequently cited biomedical scientist of the past decade, and 38th worldwide. He has published more than 200 scientific papers, and four educational children books on biology. In addition, Mr. Baeuerle is the first recipient of the Prix Europ¨¦en de l'Avenir and an elected member of the European Molecular Biology Organization (EMBO). He was appointed Honorary Professor of Immunology at the University of Munich in 2000. Mr. Baeuerle performed his Ph.D. work at the Max Planck Institute for Psychiatry in Martinsried and at the European Molecular Biology Laboratory (EMBL) in Heidelberg, obtained a Ph.D. degree in biology from the University of Munich, and performed his post-doctoral research with David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology (MIT), Cambridge, MA.

Bahija Jallal
Bahija Jallal is Vice President, Translational Sciences and Oncology at MedImmune, Inc. where she leads the preclinical and clinical biomarker functions and also directs the toxicology/pathology, clinical assays and in vivo/ex vivo biology efforts.

Frank Grams
Frank has been instrumental in setting up the newly formed Shanghai office of Roche Pharma Partnering. The office will further strengthen Roche's presence in the region and will be mainly responsible for partnering activities in Korea,

Singapore and China, as well as Taiwan and Hong Kong. Prior to taking up this post, from 2006 Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and life-cycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. During the time of these two positions, he concluded more than 80 research and technology transactions. Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked in various research functions in Roche and at Boehringer Mannheim GmbH. Frank has a degree in chemistry from the University of Heidelberg and a Ph.D. from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Martinsried).